Department of Head and Neck, Unidad de Neurociencias, Instituto Nacional de Cancerología. Ciudad de México, Mexico.
Department of Neurosurgery, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. Ciudad de México, Mexico.
Cir Cir. 2020;88(4):453-460. doi: 10.24875/CIRU.19001111.
Olfactory neuroblastoma (ONB) is a malignant neoplasm that arises from the upper nasal vault.
We present a retrospective case series and clinical analysis of 12 ONB cases.
Patients with ONB treated at Mexico´s National Cancer Institute between 2011 and 2018.
The Kadish proportion of B, C, and D stage was 16%, 58%, or 25%, respectively. Hyams Grade 1, 2, or 3 was 25%, 50%, and 25%, respectively. The most common surgical approach was the craniofacial in 5 cases (42%), followed by the transfacial in 4 cases (33%), and the endonasal endoscopic approach in 3 cases (25%). Gross total resection was achieved in 8 patients (67%). Five patients (42%) underwent a second operation due to recurrent/progressive disease. The surgical complication rate was 8.3%. Progression-free survival was 41 months and the mean overall survival was 63.6 months.
Surgical resection followed by radiotherapy, and chemotherapy for metastatic and recurrent disease provides the best outcome in terms of survival and recurrence. To the best of our knowledge, this is the first series of cases reported in Mexico.
嗅神经母细胞瘤（ONB）是一种起源于鼻腔上部的恶性肿瘤。
我们对 12 例嗅神经母细胞瘤病例进行回顾性病例系列和临床分析。
墨西哥国家癌症研究所 2011 年至 2018 年间治疗的嗅神经母细胞瘤患者。
Kadish B、C 和 D 期的比例分别为 16%、58%和 25%。Hyams 1 级、2 级和 3 级的比例分别为 25%、50%和 25%。最常见的手术方法是颅面入路 5 例（42%），其次是经面入路 4 例（33%）和经鼻内镜入路 3 例（25%）。8 例（67%）患者实现了大体全切除。5 例（42%）患者因疾病复发/进展而行二次手术。手术并发症发生率为 8.3%。无进展生存时间为 41 个月，总生存时间的平均值为 63.6 个月。
手术切除后辅以放化疗治疗转移性和复发性疾病，可获得最佳的生存和复发结局。据我们所知，这是墨西哥首例此类病例系列报告。
